3,4-Methylenedioxymethamphetamine (MDMA, ecstasy)-induced egr-1 mRNA in rat brain: Pharmacological manipulation

European Journal of Pharmacology

Volumn 402, Issue 3, 2000, Pages 215-222

  Shirayama, Yukihiko ^a,b   Hashimoto, Kenji ^a,c   Iyo, Masaomi ^a,c   Watanabe, Kei Ichiro ^a   Higuchi, Teruhiko ^b   Minabe, Yoshio ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^b SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

5 HT (5 hydroxytryptamine, serotonin) transporter; Egr 1 (zif 268); Immediate early gene; MDMA (3,4 methylenedioxymethamphetamine)

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DIZOCILPINE; DOPAMINE 1 RECEPTOR; EPLIVANSERIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN TRANSPORTER;

ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN TISSUE; GENE ACTIVITY; IMMEDIATE EARLY GENE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN SITU HYBRIDIZATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR INTRINSIC ACTIVITY; TISSUE DISTRIBUTION;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; BRAIN CHEMISTRY; DIZOCILPINE MALEATE; DNA-BINDING PROTEINS; DOPAMINE ANTAGONISTS; EARLY GROWTH RESPONSE PROTEIN 1; EXCITATORY AMINO ACID ANTAGONISTS; FLUOROBENZENES; HALLUCINOGENS; IMMEDIATE-EARLY PROTEINS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PAROXETINE; PHENOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; TRANSCRIPTION FACTORS;

EID: 0034714205     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00521-5     Document Type: Article

References (34)

1. Beckmann A., Wilce P.A. Egr transcription factors in the nervous system. Neurochem. Int. 31:1997;477-510.
2. Berretta S., Robertson H.A., Graybiel A.M. Dopamine and glutamate agonists stimulate neuron-specific expression of fos-like protein in the striatum. J. Neurophysiol. 68:1992;767-777.
3. Bolla K.I., McCann U.D., Ricaurte G.A. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology. 51:1998;1532-1537.
4. Gass P., Herdegen T., Bravo R., Kiessling M. Induction and suppression of immediate early genes in specific rat brain regions by the non-competitive N-methyl-D-aspartate receptor antagonist MK-801. Neuroscience. 53:1993;749-758.
5. Gerra G., Zaimovic A., Giucastro G., Maestri D., Monica C., Sartori R., Caccavari R., Delsignore R. Serotonergic function after (+/-) 3,4-methylene-dioxymethamphetamine ("Ecstasy") in humans. Int. Clin. Psychopharmacol. 13:1998;1-9.
6. Graybiel A.M., Moratalla R., Robertson H.A. Amphetamine and cocaine induce drug-specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivisions of the striatum. Proc. Natl. Acad. Sci. U. S. A. 87:1990;6912-6916.
7. Green A.R., Cross A.J., Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology. 119:1995;247-260.
8. 3H]6-nitroquipazine-labeled 5-hydroxytryptamine uptake sites in rat brain by 3,4-methylenedioxymethamphetamine. Fundam. Clin. Pharmacol. 4:1990;635-641.
9. 3H]6-nitroquipazine. Res. Commun. Subst. Abuse. 13:1992;191-201.
10. Hashimoto K., Tomitaka S., Narita N., Minabe M., Iyo M. Induction of Fos protein by 3,4-methylenedioxymethamphetamine (Ecstasy) in rat brain: regional differences in pharmacological manipulation. Addict. Biol. 2:1997;317-326.
11. Hata N., Nishikawa T., Umino A., Takahashi K. Evidence for involvement of N-methyl-D-aspartate receptor in tonic inhibitory control of dopaminergic transmission in rat medial frontal cortex. Neurosci. Lett. 120:1990;101-104.
12. Hegadoren K.M., Baker G.B., Bourin M. 3,4-methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci. Biobehav. Rev. 23:1999;539-553.
13. Henry J.A., Jeffreys K.J., Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("Ecstasy"). Lancet. 340:1992;384-387.
14. Herdegen T., Kovary K., Buhl A., Bravo R., Zimmermann M., Gass P. Basal expression of the inducible transcription factors c-Jun, JunB, JunD, c-Fos, FosB, and Krox-24 in the adult rat brain. J. Comp. Neurol. 354:1995;39-56.
15. Hughes P., Dragunow M. Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol. Rev. 47:1995;133-178.
16. Kaczmarek L., Chaudhuri A. Sensory regulation of immediate-early gene expression in mammalian visual cortex: implications for functional mapping and neural plasticity. Brain Res. Rev. 23:1997;237-256.
17. Karreman M., Westerink B.H.C., Moghaddam B. Excitatory amino acid receptors in the ventral tegmental area regulate dopamine release in the ventral striatum. J. Neurochem. 67:1996;601-607.
18. 2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology. 15:1996;116-124.
19. 1 and N-methyl-D-aspartate receptors. Proc. Natl. Acad. Sci. U. S. A. 91:1994;8537-8541.
20. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effects of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet. 352:1998;1433-1437.
21. McKenna D.J., Peroutka S.J. The neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine, "ecstasy" J. Neurochem. 54:1990;14-22.
22. Milbrandt J. A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science. 238:1987;797-799.
23. Moratalla R., Robertson H.A., Graybiel A.M. Dynamic regulation of NGFI-A (zif268, egr1) gene expression in the striatum. J. Neurosci. 12:1992;2609-2622.
24. Morgan M.J. Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology. 141:1999;30-36.
25. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1997;Academic Press, San Diego, CA, USA.
26. Ropero-Miller J.D., Goldberger B.A. Recreational drug. Current trends in the 90s. Clin. Lab. Med. 18:1999;727-746.
27. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240:1987;1-7.
28. Schimidt C.J., Fadayel G.M., Sullivan C.K., Taylor V.L. 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol. 223:1992;65-74.
29. Shirayama Y., Hashimoto K., Matsuki H., Tsunashima K., Iyo M., Higuchi T., Minabe Y. Increased expression of zif268 mRNA in rat retrosplenial cortex following administration of phencyclidine. Brain Res. 839:1999;180-185.
30. Solowij N. Ecstasy (3,4-methylenedioxymethamphetamine). Curr. Opin. Psychiatry. 6:1993;411-415.
31. 2 dopamine receptor antagonists on acute amphetamine- or methamphetamine-induced up-regulation of zif268 mRNA expression in rat brain. J. Neurochem. 6:1995;2706-2715.
32. Wang J.Q., McGinty J.F. Acute methamphetamine-induced zif268, preprodynorphin, and preproenkephalin mRNA expression in rat striatum depends on activation of NMDA and kainate/AMPA receptors. Brain Res. Bull. 39:1996;349-357.
33. Wolf M.E. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog. Neurobiol. 54:1998;679-720.
34. Worley P.F., Christy B.A., Nakabeppu Y., Bhat R.V., Cole A.J., Baraban J.M. Constitutive expression of zif268 in neocortex is regulated by synaptic activity. Proc. Natl. Acad. Sci. U. S. A. 88:1991;5106-5110.